"Thiadiazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013830
|
| MeSH Number(s) |
D02.886.675.867 D03.383.129.708.867
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiadiazoles".
Below are MeSH descriptors whose meaning is more specific than "Thiadiazoles".
This graph shows the total number of publications written about "Thiadiazoles" by people in this website by year, and whether "Thiadiazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiadiazoles" by people in Profiles.
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
-
Piezo1 regulates meningeal lymphatic vessel drainage and alleviates excessive CSF accumulation. Nat Neurosci. 2024 May; 27(5):913-926.
-
Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate. 2021 09; 81(12):799-811.
-
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells. 2021 04 06; 10(4).
-
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Cancer Lett. 2021 04 01; 502:180-188.
-
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J. 2019 10 01; 9(10):80.
-
GLS2 is protumorigenic in breast cancers. Oncogene. 2020 01; 39(3):690-702.
-
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia. Mol Cancer Ther. 2019 11; 18(11):1937-1946.
-
GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib. Drug Res (Stuttg). 2018 Aug; 68(8):436-443.
-
Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. Sci Rep. 2017 11 23; 7(1):16159.